What if treating mental health didn’t mean taking a pill every day for the rest of your life? We invested in Eywa Biotech because they are building for a different future. Moving mental healthcare from chronic daily medication toward medicines that can create meaningful, lasting change with one or a few treatments.
Now they are taking orders for their first GMP psilocybin capsules in 25mg, 5mg and placebo.
They are being produced for clinical trials and research, and for regulated and emerging markets including Australia, the Czech Republic and Switzerland.
Researchers, clinics and pharmaceutical companies interested in working with Eywa can reach victoria@eywa.bio or pablo@eywa.bio.
And they’re not stopping there. Victoria Costa Paz and her team are using synthetic biology to make these medicines more accessible and scalable.